Hadassah Medical Organization (HMO) researchers have shown that patients with progressive multiple sclerosis (MS) have significant improvements in cognition, neurological function tests, and quality of life following repeated intrathecal injection of autologous, bone marrow-derived mesenchymal stem cells (MSC).

Presenting their study to the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024, the Hadassah MS team led by Prof. Dimitrios Karussis, MD, Director of the Multiple Sclerosis Center at Hadassah Medical Organization, working with Petrou Panayiota, MD, and Ibrahim Kassis, MD, reported no serious adverse events among the 23 participants.

 “The main takeaway is that this treatment can be effective in a way that other medicines are not,” Dr. Panayiota, Senior expert of the Multiple Sclerosis Center of the Neurology Department explained. “Importantly, with this treatment, we see not just benefit but improvement. We do not

 usually see that in progressive patients.”

You can read more here: https://www.prnewswire.com/news-releases/neurogenesis-reports-positive-results-from-phase-2-extension-study-in-progressive-multiple-sclerosis-treated-with-ng-01-cell-therapy-302086449.html